Scientific cooperation for transfer of intellectual property for creation for prototype of test system.colleagues at Ulm and European universities (Birmingham, Kopenhagen, Bratislava).Since 2017 Cooperation with Thermo Fisher Coating and handling of Paramagnetic Beads Cooperation partners Scientific collaboration with Since 2015: Paramagnetic beads application in bridge TRAb assay (patent application) 1998-2018: Cooperation with IVD companies (transfer of our prototypes) TSHR expression, antibody detection and quantification by immunoprecipitation (patenting) 2005 – today: At KreLo GmbH Medical DiagnosticsĢ005: TSHR antibody detection and quantification by bridge technology (patenting) History of pioneering in „In vitro“ diagnostic (IVD) development 1971 – 1993: At university of Ulmġ971: Replacing bioassays by radioimmunoassays (T4, T3, rT3, TSH)ġ973: First description of low T3 (euthyroid sick) syndromġ982: Proteomics (T3 responsive liver proteins)ġ993: Detection of TSHR and T3 receptor mutation, functional as peripheral hyperthyroidism 1998 – 2004: At university of Ulm and personal enterprise INNOVATIVE MEDICINE Further new technologies are based on paramagnetic beads technology. This method was transferred to Immulit TSI of Siemens Healthcare. KreLo GmbH Medical Diagnostics developed the first test for the direct detection of Graves‘ disease inducing autoantibodies with a new technology, called bridge assay, on microtiter plates (sTRAb). The work therein was focused on research and development of IVD-Assay in autoimmunity. KreLo GmbH Medical Diagnostic was founded in 2004 at the Biotechnology Center in Ulm (TFU) and began as a Start up by spin off from University of Ulm.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |